Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Mylan N.V.    MYL   NL0011031208

MYLAN N.V.

(MYL)
  Report  
Delayed Quote. Delayed Nasdaq - 11/15 04:00:00 pm
17.7 USD   +2.55%
11/12MYLAN N : and Pfizer Say Combined -Upjohn to Be Called Viatris
DJ
11/05MYLAN N : 425
PU
11/05Health Care Down as Mylan, Mallinckrodt Weigh -- Health Care Roundup
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Mylan N : shares slide after warning of hit to revenue

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/05/2019 | 01:06pm EST
Logo of Mylan Laboratories, a company primarily engaged in the commercialization of generic drugs is pictured in Merignac near Bordeaux

Generic drugmaker Mylan NV said on Tuesday reevaluation of its portfolio of medicines will continue next year and cautioned of a hit to revenue, and its shares nearly 6%.

Mylan, which posted higher-than-expected third-quarter profit with the help of cost constraints, said it would reassess products it sells outside United States and had nearly completed its review of U.S. products.

The review process should not affect net profit, President Rajiv Malik said on a conference call with analysts. However, "it does have an impact in our top line results."

Mylan in July agreed to merge with Pfizer Inc's Upjohn unit that sells off-patent branded drugs. The company will be able to leverage a strong base in Asia through Upjohn, headquartered in China, a prime market for well-known older brands such as Pfizer's cholesterol drug Lipitor and erectile dysfunction treatment Viagra.

Mylan provided few new details on the merger plan, but said it still expects the deal to close in the middle of next year.

"This merger will solve nothing," said Cowen and Co analyst Ken Cacciatore, adding that the Pfizer deal will not halt the problem of "constant downward deterioration in the base businesses."

North America business, which accounts for more than a third of Mylan's total revenue, has been grappling with intense competition, falling generic drug prices and expenses related to fixing issues at its Morgantown manufacturing plant in West Virginia.

Newer drugs, including Wixela and Yupelri for respiratory ailments, helped North American sales rise 8% to $1.09 billion (£846.93 million), marking the second consecutive quarter of growth after years of decline.

Mylan warned that 2019 sales from Wixela could fall short of its earlier target.

"While our launch of Wixela has been very successful, full year sales are anticipated to be a bit short of original expectations as a result of the aggressive (market) share retention actions," Chief Financial Officer Kenneth Parks said, without elaborating on whether that referred to offering discounts or rebates.

The company on Tuesday also narrowed its full-year adjusted earnings forecast range to between $4.20 and $4.40 per share, from its prior view of $3.80 to $4.80.

Excluding items, Mylan earned $1.17 per share in the quarter, beating analysts' estimates by 4 cents, according to IBES data from Refinitiv.

Total revenue increased 3.5% to $2.96 billion, missing analysts' estimates of $3.01 billion, partly hurt by the stronger dollar's effect on foreign exchange rates.

Mylan shares were down 5.8% at $18.58.

By Saumya Joseph and Aakash B

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MYLAN N.V.
11/12MYLAN N : and Pfizer Say Combined -Upjohn to Be Called Viatris
DJ
11/05MYLAN N : 425
PU
11/05Health Care Down as Mylan, Mallinckrodt Weigh -- Health Care Roundup
DJ
11/05MYLAN N : shares slide after warning of hit to revenue
RE
11/05MYLAN N : shares slide after warning of hit to revenue
RE
11/05MYLAN N : Q3 2019 Non-GAAP Reconciliations
PU
11/05MYLAN N : Reports Third Quarter 2019 Results and Updates 2019 Guidance
PR
11/01DIABETES AWARENESS : Learn More About the Condition that is Estimated to Affect ..
PU
11/01Amgen To Invest In Chinese Biotech -- WSJ
DJ
10/31MYLAN N.V. : quaterly earnings release
More news
Financials (USD)
Sales 2019 11 557 M
EBIT 2019 3 217 M
Net income 2019 490 M
Debt 2019 11 832 M
Yield 2019 -
P/E ratio 2019 14,6x
P/E ratio 2020 8,85x
EV / Sales2019 1,81x
EV / Sales2020 1,81x
Capitalization 9 136 M
Chart MYLAN N.V.
Duration : Period :
Mylan N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MYLAN N.V.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 25,21  $
Last Close Price 17,70  $
Spread / Highest target 97,7%
Spread / Average Target 42,4%
Spread / Lowest Target 1,69%
EPS Revisions
Managers
NameTitle
Heather M. Bresch Chief Executive Officer & Executive Director
Rajiv Malik President & Executive Director
Robert J. Coury Executive Chairman
Kenneth Scott Parks Chief Financial Officer
Andrea B. Miller Head-Global Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
MYLAN N.V.-35.40%9 136
JOHNSON & JOHNSON4.56%355 145
ROCHE HOLDING AG20.79%255 382
MERCK AND COMPANY11.11%216 154
PFIZER-14.59%206 312
NOVARTIS18.75%202 726